Icon ... I may be mis-reading, mis-interpreting, mis-thinking ... but my take on bear's post is in line with my own "questions/contemplations" pending FLD ... that, there is the potential and possibility that BoM could have been a small "miss" overall, with one statin making the grade even if only slightly, while the other missed just enough to pull down the overall grade? ... entirely speculation, and possibly just wishful thinking, but "what if" FLD shows that to be the case, in a meaningful and very promising way?

Haven't we all agreed if BoM succeeded (by a milimeter) it would be ground breaking data and success compared with currently available regimens. So "what if" FLD shows Apa/Rosu met the rigorous standards on it's own merits, and delivered ground breaking results on it's own merits within the sub-study?

Do you throw the baby out with the bath water? ...

"IF" that is the case, and the basis for some renewed optimism in the markets? ... and from the PR, despite the expected disappointment of missing the endpoint?

I'm not betting the farm on this theory, just VERY open-minded and somewhat "optimistic" to the possibility, and the potential for a cogent argument for fast-tracking "if" FLD offers undeniable sub-study data support for safety and efficacy.

There is a lot at stake clinically for patients potentially, ... and a CRITICALLY over-burdened healthcare cost problem as well ...